Projected budget impact and access to new drugs in Brazil
Brazil's Constitution defines health as a right of all and a duty of the State, and the Unified Health System (SUS) translates that promise into free access to medicines at the point of care.1 Since Law 12,401/2011, new drugs enter the SUS through the National Committee for Health Technology Incorporation (CONITEC, for the acronym in Portuguese), which must weigh clinical evidence, cost-effectiveness and budget impact.2 In The Lancet Regional Health – Americas, Curado and colleagues3 step back from case-by-case appraisal and ask a system-level question: taken together, did the projected budget impacts of the 199 drugs incorporated between 2012 and 2024 add up to something the SUS could afford?
Authors
- Ângelo Maiolino (ORCID: https://orcid.org/0000-0003-0140-9548)
Institutions
- Universidade Federal do Rio de Janeiro (BR)
- Instituto de Oncologia do Paraná (BR)
- Sociedade Brasileira de Oncologia Clínica (BR)
Publication Details
- Journal
- The Lancet Regional Health - Americas
- Published
- 2026-11-17
- DOI
- https://doi.org/10.1016/j.lana.2026.101712
- Primary Topic
- Pharmaceutical Economics and Policy
- Type
- article
- Field-Weighted Citation Impact
- 0.00